T
Traws Pharma, Inc. (TRAW)
NCM – Real vaqt narxi. Valyuta: USD
0.83
-0.01 (-0.60%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
0.83
+0.00 (0.47%)
Bozordan keyin: Jun 26, 2026, 7:44 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
0.83
-0.01 (-0.60%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
0.83
+0.00 (0.47%)
Bozordan keyin: Jun 26, 2026, 7:44 PM EDT
Traws Pharma, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, nafas olish yo'llari virusli kasalliklari va saraton uchun kichik sintetik molekulalarni ishlab chiqadi. Kompaniya gripp va COVID-19 uchun tadqiqotdagi yangi davolash usullarini ishlab chiqmoqda, ular davolashga chidamliligini bartaraf etishga qaratilgan, masalan, COVID-19ni davolash uchun ishlab chiqilayotgan ingibitor TRX01 (Ratutrelvir); va qush grippi va mavsumiy grippni davolash uchun ishlab chiqilayotgan endonukleaza ingibitori Tivoxavir marboxil. Shuningdek, u qattiq o'smalar va gematologik malignansiyalarda yagona vosita sifatida yoki boshqa saratonga qarshi davolash usullari bilan birgalikda ko'p maqsadli kinaza ingibitori bo'lgan narazatsiklibni; va turli xil saraton turlarini tadqiq qilish uchun yolg'iz yoki birgalikda qo'llaniladigan rigosertibni ishlab chiqmoqda. U SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd. va Temple University bilan litsenzion kelishuvga ega. Kompaniya ilgari Onconova Therapeutics, Inc. nomi bilan tanilgan va 2024 yil aprel oyida Traws Pharma, Inc. nomini o'zgartirgan. Traws Pharma, Inc. 1998 yilda tashkil etilgan va shtab-kvartirasi Nyu-taun, Pensilvaniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Charles David Pauza Ph.D. | Chief Scientific Officer of Virology |
| Dr. Iain D. Dukes DPHIL, M.A., Ph.D. | CEO, Secretary & Director |
| Dr. Nikolay Savchuk Ph.D. | COO & Director |
| Dr. Robert R. Redfield M.D. | Chief Medical Officer |
| Dr. Victor Mandia Moyo M.D. | Chief Medical Officer of Oncology |
| Mr. Charles Parker | Chief Financial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-12 | 8-K | tm2617872d1_8k.htm |
| 2026-05-29 | DEFA14A | tm261586d5_defa14a.htm |
| 2026-05-29 | DEF 14A | tm261586-3_def14a.htm |
| 2026-05-27 | 8-K | tm2615712d1_8k.htm |
| 2026-05-26 | 8-K | tm2615554d1_8k.htm |
| 2026-05-19 | PRE 14A | tm261586-1_pre14a.htm |
| 2026-05-15 | 8-K | tm2614707d1_8k.htm |
| 2026-05-15 | 10-Q | traw-20260331x10q.htm |
| 2026-05-08 | S-3 | tm2612767d1_s3.htm |
| 2026-04-30 | 10-K/A | traw-20251231x10ka.htm |